tVNS to treat respiratory symptoms associated with COVID-19

Share on facebook
Share on twitter
Share on google
Share on linkedin
Share on email
Share on print

Use of non-invasive vagus nerve stimulation to treat respiratory symptoms associated with COVID-19: A theoretical hypothesis and early clinical experience.

Abstract
OBJECTIVES: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a pandemic with no specific therapeutic agents and substantial mortality, and finding new treatments is critical. Most cases are mild, but a significant minority of patients develop moderate to severe respiratory symptoms, with the most severe cases requiring intensive care and/or ventilator support. This respiratory compromise appears to be due to a hyperimmune reaction, often called a cytokine storm. Vagus nerve stimulation has been demonstrated to block production of cytokines in sepsis and other medical conditions. We hypothesize that non-invasive vagus nerve stimulation (nVNS) might provide clinical benefits in patients with respiratory symptoms similar to those associated with COVID-19.
MATERIALS AND METHODS: Information on two case reports was obtained via email correspondence and phone interviews with the patients.
RESULTS: Both patients reported clinically meaningful benefits from nVNS therapy. In Case 1, the patient used nVNS to expedite symptomatic recovery at home after hospital discharge and was able to discontinue use of opioid and cough suppressant medications. In Case 2, the patient experienced immediate and consistent relief from symptoms of chest tightness and shortness of breath, as well as an improved ability to clear his lungs.
CONCLUSIONS: Preliminary observations and a strong scientific foundation suggest that nVNS might provide clinical benefits in patients with COVID-19 via multiple mechanisms.

PMID: 32342609 [PubMed – as supplied by publisher]

Neuromodulation. 2020 Apr 27;:

Authors: Staats P, Giannakopoulos G, Blake J, Liebler E, Levy RM

Join Our Newsletter


Mike

Mike

Comments?